# US 12,111,313 B2 · Chelator-coated field effect transistor and devices and methods using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,111,313 B2
- Document ID: US12111313B2
- Status: Granted
- Kind: B2
- Application number: 17/264,281
- Filed: 2019-08-14
- Published: 2021-09-23
- Granted: 2024-10-08
- Earliest claimed: 2018-08-14
- Assignees: Autonomous Medical Devices Inc.
- Applicants: Sensor-Kinesis Corporation
- Inventors: Roger D. Kornberg
- Web page: https://patentgrep.com/patent/US12111313B2

## CPC

- G01N 33/54373: {involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings}
- G01N 27/4145: {specially adapted for biomolecules, e.g. gate electrode with immobilised receptors}
- G01N 27/4146: {involving nanosized elements, e.g. nanotubes, nanowires}
- G01N 33/5432: {Liposomes or microcapsules}
- G01N 33/5438: {Electrodes}
- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- G01N 33/84: involving inorganic compounds or pH
- G01N 2458/30: Electrochemically active labels
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A field effect transistor comprising a chelator or derivatized chelator, a device for detecting a marker in a sample comprising said sensor, a method for detecting metal ions in a sample comprising said sensor or device and a sensor and method for detecting a marker in a sample.

## Claims

### Claim 1

A method for the detection of a target marker in a solution including charged ions and unrelated ions comprising:
providing a liposome in solution containing metal ions, the liposome including a detection antibody configured to bind a target marker;
providing a field-effect transistor with a source-drain channel comprising a surface functionalized with both a capture antibody to selectively bind to the target marker and a metal ion chelator or metal ion derivatized chelator;
selectively binding the target marker to the detection antibody included with the liposome;
selectively binding the target marker to the capture antibody to dispose the target marker and bound liposome to the source-drain channel of the field-effect transistor;
releasing the metal ions from the liposome;
selectively binding the metal ion chelator or metal ion derivatized chelator disposed on the functionalized surface of the source-drain channel with the metal ions released from the liposome; and
causing a change in current in the field-effect transistor as a result of the selective binding of the metal ion chelator or metal ion derivatized chelator with the metal ions released from the liposome without interference of the detection of the metal ions by screening oppositely charged ions and unrelated ions in the solution; and
wherein the change in current is indicative of detection of the target marker.

### Claim 2 (depends on 1)

The method of claim 1, wherein the field-effect transistor comprises a substrate comprising gallium nitride.

### Claim 3 (depends on 1)

The method of claim 1, wherein the field-effect transistor further comprises a carbon nanotube.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the carbon nanotube is at least partially interposed between the source and the drain.

### Claim 5 (depends on 1)

The method of claim 1, wherein the metal ion is Ca2+.

### Claim 6 (depends on 1)

The method of claim 1, wherein the metal ion is Fe2+ or Fe3+.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the chelator or derivatized chelator is selected from the group consisting of deferasirox; deferiprone; deferoxamine; desferrioxamine; desferrithiocin[2-(3-hydroxypyridin-2-yl)-4-methyl-4,5-dihyrothiazole-4-carboxylic acid; clioquinol; O-trensox (Tris-N-(2-aminoethyl-[8-hydroxyquinoline-5-sulfonato-7-carboxamido] amine); tachpyr (N,N′,N″-tris(2-pyridylmethyl)-cis,cis-1,3,5-triamino-cyclohexane); dexrazoxane; triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone); pyridoxal isonicotinoyl hydrazone; di-2-pyridylketone thiosemicarbazone series; flavan-3-ol; curcumin; apocynin; kolaviron; floranol; baicalein; baicalin; Ligusticum wallichi Francha (ligustrazine); quercetin; epigallocatechin gallate; theaflavin; phytic acid; genistein (5,7,4′-tri-hydroxyisoflavone); EDTA; NTA; HBED, o-Phenanthroline monohydrate; Pyridoxal Isonicotinoyl Hydrazone, 2,2prime-Dipyridyl, (S)-1-(p-Bromoacetamidobenzyl)ethylenediaminetetraacetic Acid, (S)-1-(4-Aminoxyacetamidobenzyl)ethylenediaminetetraacetic Acid; and derivatives thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the metal ion is Mg2+.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the chelator or the derivatized chelator is selected from the group consisting of EDTA, EGTA, HEDTA, NTA and derivatives thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the metal ion is Mn2+.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the chelator or the derivatized chelator is selected from the group consisting of EDTA; EGTA; HEDTA; NTA; triethylenetetramine-N,N,N′,N″,N′″,N′″-hexaacetic acid (TTHA); diethylenetriaminepentaacetic acid (DTPA); DPTA; DPTA-OH; HBED; and derivatives thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the metal ion is Cu2+ or Cu3+.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the chelator or the derivatized chelator is selected from the group consisting of EDTA; NTA; D-Penicillamine (DPA); Tetraethylenetetraamine (TETA); clioquinol and derivatives thereof.

### Claim 14 (depends on 1)

W The method of claim 1, wherein the metal ion is Zn2+.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the chelator or the derivatized chelator is selected from the group consisting of ADAMTS-5 Inhibitor; N,N,N′,N′-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN); EDPA; 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA); CaEDTA; EDTA; EGTA; Tricine; ZX1; 4-{[2-(bis-pyridin-2-ylmethylamino)ethylamino]methyl}phenyl)methanesulfonic acid (DPESA); [4-({[2-(bis-pyridin-2-ylmethylamino)ethyl]pyridin-2-ylmethylamino}-methyl)phenyl]methanesulfonic acid (TPESA); and derivatives thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the metal ion is K+.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the chelator or the derivatized chelator is selected from the group consisting of calcium polystyrene sulfonate; sodium polystyrene sulfonate; patiromer; sodium zirconium cyclosilicilate; D-tartrate monobasic; and derivatives thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein the metal ion is a heavy metal ion.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the heavy metal ion is selected from the group consisting of As+3, Hg+2, Sb+3, and Au+.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the chelator or the derivatized chelator is selected from the group consisting of Dimercaprol (2,3-dimercapto-1-propanol); Sodium 2,3-dimercaptopropanesulfonate monohydrate; 2,3-Dimercapto-1-propanesulfonic acid sodium salt; and derivatives thereof.

### Claim 21 (depends on 1)

The method of claim 1, wherein the target marker is a biomarker, an environmental marker, an allergen, or a microorganism.

### Claim 22 (depends on 1)

The method of claim 1, wherein the metal ions are is released from the liposome by contacting the liposome with a detergent.